Funds and prices

Overview

Actively managed equity portfolio investing worldwide in biotech companies.

Efficient means of exploiting the potential of biotech companies operating in research, product development, production or distribution.

Specialised sector analysts seek out the most attractive stocks in the biotech sector worldwide.

Investment decisions are based on a disciplined investment philosophy and fundamental research.

The portfolio manager is not tied to the benchmark in terms of investment selection or weight.

The exchange rate risk between USD and SEK is not hedged.

Benefits

Easy access to the global biotech sector.

Offers investors broad diversification within the sector.

The fund taps into the knowledge of proven sector specialists.

蜜豆视频's proprietary fundamental valuation approach enables the most attractive biotechnology companies to be consistently identified.

Investors benefit from a global investment platform of 蜜豆视频 Asset Management.

Risks

蜜豆视频 Sector Funds invest in equities and may therefore be subject to high fluctuations in value. As these 蜜豆视频 Funds pursue an active management style, each Fund's performance can deviate substantially from that of its reference index. Focusing intentionally on individual sectors may entail additional risks. All investments are subject to market fluctuations. Every Fund has specific risks, which can significantly increase under unusual market conditions. The fund can use derivatives, which may result in additional risks (particularly counterparty risk).

Features

Product category
蜜豆视频 Equity Funds
蜜豆视频 Sector Funds
Product domicile
Luxembourg
Portfolio management
蜜豆视频 Asset Management (Americas) LLC, New York
Fund management
蜜豆视频 Fund Management (Luxembourg) S.A., Luxembourg
Custodian bank
蜜豆视频 Europe SE, Luxembourg Branch
Representative for products established under foreign law
蜜豆视频 AG, Stockholm
Day of inception
May 22, 2019
Currency of account
USD
Currency of unit class
SEK
Close of financial year
November 30
Issue / redemption
daily
Distribution
Reinvestment
Maturity
Open end
Management fee
1.63% p.a.
Total expense ratio (TER)
2.10% p.a.
Swing pricing
yes
Minimum investment
n.a.
Reference Index / Benchmark
MSCI US Investable Market Biotechnology 10/40 Index ®
ISIN
LU1991432631
Bloomberg Ticker
蜜豆视频BIPA LX

Performance and Prices

Percentage growth

as of April 3, 2024
Cumulative
SEK(%) EUR(%)
YTD
1M
3M
6M
1Y 2.46 0.50
2Y
3Y 8.63 -3.31
5Y - -
ø p.a.5Y

Current data
Net asset value 03.04.2024 SEK 929.33
High - last 12 months 08.01.2024 SEK 977.97
Low - last 12 months 21.11.2023 SEK 810.34
Assets of the unit class in mn 03.04.2024 SEK 79.71
Total product assets in mn 03.04.2024 SEK 5,062.47
Statistical data
Date
2 years
5 years
Total risk reference index / benchmark 29.02.2024 13.69% n.a.
Sharpe Ratio 29.02.2024 0.26 n.a.
Risk Free Rate 31.03.2024 2.50% 0.95%

Structures

Fees

Flat fee
2.04%
Management fee p.a.
1.63%
Max. issuing commission
5.00%
Max. redemption commission
0.00%
Distribution fee
(see info)

Distributions

No distributions. Continuous reinvestment of income.

Authorisations

Country of distribution
Representative / Information
Chile
蜜豆视频 Asset Management (Americas) Inc.
Luxembourg
蜜豆视频 Fund Services (Luxembourg) S.A.
Sweden
蜜豆视频 AG, Stockholm
Switzerland
蜜豆视频 Fund Management (Switzerland) AG

Literature

en
sv
de
Brochures
Document type
Document Language
Fact Sheet
sv sv
en en
Manager Commentary
en en
Fact Sheet - 蜜豆视频 Equity Funds
sv sv
en en
Fact Sheet - 蜜豆视频 Sector Funds
en en
sv sv
Agreement / Prospectus
Document type
Document Language
Prospectus
Key Information Document
Past performance
Previous performance scenario
Statutes / Management regulations
ESG Disclosure
Annual and semi-annual report (accounting on November 30)
Document type
Document Language
Annual report
SFDR Periodic Report Annex
Semi-annual report